<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523690</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00072940</org_study_id>
    <nct_id>NCT02523690</nct_id>
  </id_info>
  <brief_title>Evaluating Muscle Weakness Improvement With Lorcaserin in ICU</brief_title>
  <acronym>EMILI</acronym>
  <official_title>Evaluating Lorcaserin Drug Therapy For ICU-Acquired Weakness: A Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ICU acquired muscle weakness is a significant problem in patients recovering from critical
      illness. This trial will evaluate the safety and efficacy of a drug in improving muscle
      weakness in critically ill patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in handgrip strength from baseline as measured by hand dynamometer</measure>
    <time_frame>2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in handgrip strength from baseline as measured by hand dynamometer</measure>
    <time_frame>2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in manual muscle strength from baseline as measured by the Medical Research Council (MRC) score</measure>
    <time_frame>2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in manual muscle strength from baseline as measured by the Medical Research Council (MRC) score</measure>
    <time_frame>2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps strength from baseline as measured by handheld dynamometer</measure>
    <time_frame>2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps strength from baseline as measured by handheld dynamometer</measure>
    <time_frame>2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Muscle Weakness</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years old

          2. Sepsis [ ≥2 Systemic Inflammatory Response Syndrome (SIRS) Criteria AND known or
             suspected infection]

          3. Muscle weakness [Medical Research Council sum score &lt;48/60 or handgrip strength &lt;11 kg
             in men and &lt;7 kg in women]

          4. Obey Commands [Score for DeJonghe Awakening Score of ≥3/5]

        Exclusion Criteria:

          1. Severe renal insufficiency [Creatinine Clearance &lt;30 mL/min - or receiving dialysis]

          2. Acute infectious or auto-immune hepatitis, acute liver failure or a history of
             cirrhosis without liver transplant

          3. History of psychosis

          4. Bradycardia, or 2nd or 3rd degree AV block without pacemaker

          5. History of valvular heart disease without valve replacement

          6. History of priapism

          7. Pre-existing cognitive impairment

          8. Receiving drugs with serotonergic effects and/or CYP2D6 substrates which cannot be
             substituted stopped or titrated.

          9. Receiving Sulfonylurea medication at the time of the study

         10. Prior neuromuscular or central nervous system disease, including pre-existing
             neuropathy

         11. Inability to perform study's muscle strength assessments based on patient's baseline
             status prior to hospital admission

         12. Unable to receive, or unlikely to absorb study drug (e.g. bowel obstruction, ischemia,
             or infarction; short gut syndrome)

         13. Body mass index &gt;40

         14. Patient not expected to survive &gt;4 days

         15. Pregnancy or lactation

         16. Allergy to lorcaserin or lorcaserin taken in the prior 7 days

         17. Enrolled in another interventional drug or physical rehabilitation trial

         18. Physician declines for patient to be enrolled

         19. Patient or proxy declines consent

         20. Unable to reach proxy for consent

         21. Non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale M Needham, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

